A Clinically Relevant Model for Screening Anti-Seizure Drugs in Chronic Epileptic Rats

**Advantages**
- Fast and Multifaceted Results
- Animals demonstrate pharmacoresistance to clinically relevant ASDs
- Matches the clinical treatment of patients

---

<table>
<thead>
<tr>
<th>Placebo</th>
<th>CBZ</th>
<th>VPA</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 week</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 weeks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Disadvantages**
- Costly
  - However, less than a Phase 1 Clinical Trial
- Complex
  - However, custom software helps
- Limited Throughput
  - However, only the most promising potential ASDs